Somerville, MA, United States of America

Michael DePrima

USPTO Granted Patents = 5 

Average Co-Inventor Count = 13.0

ph-index = 3

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2013-2023

Loading Chart...
5 patents (USPTO):

Title: The Innovative Contributions of Michael DePrima

Introduction

Michael DePrima, an accomplished inventor based in Somerville, MA, has made significant strides in the field of biotechnology. He holds an impressive portfolio of five patents, each demonstrating his commitment to advancing medical science and improving patient outcomes.

Latest Patents

Among his notable inventions are two recent patents focused on Anti-ErbB3 antibodies. These monoclonal antibodies specifically target and inhibit the activation of the epidermal growth factor receptor-related member, ErbB3/HER3. The relevance of these antibodies lies in their potential applications in treating cell proliferative diseases and disorders, including various forms of cancer associated with the aberrant activation of ErbB3/HER3.

Career Highlights

Michael DePrima is currently associated with Aveo Pharmaceuticals, Inc., a company dedicated to developing innovative therapies for cancer patients. His work in this biopharmaceutical firm has positioned him at the forefront of research and discovery in oncology.

Collaborations

Throughout his career, DePrima has partnered with esteemed colleagues such as Sylvie Vincent and William M Winston, Jr. These collaborations underscore the importance of teamwork in advancing scientific research and the development of effective medical therapies.

Conclusion

Michael DePrima's contributions to the field of biotechnology through his patents and collaborative efforts exemplify the impact that dedicated inventors can have on healthcare. His work not only fosters innovation but also paves the way for potential breakthroughs in cancer treatment, reflecting a true commitment to addressing significant health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…